People Using GLP-1s, Like Ozempic, Wegovy, Less Likely to Exercise Despite Benefits
Research presented at the Endocrine Society's 2026 annual meeting in Chicago has identified a counterintuitive public health concern: individuals initiating treatment with GLP-1 receptor agonists, the class of medications that includes widely prescribed drugs such as Ozempic and Wegovy, demonstrate measurably reduced physical activity levels despite substantial weight loss. This finding emerges from analysis of data derived from the National Institutes of Health's All of Us Research Program, which linked comprehensive health records with objective activity monitoring from Fitbit devices. The study examined 753 individuals with obesity who had documented activity data both before and after commencing GLP-1 therapy, revealing a consistent pattern of diminished movement across the cohort. Among the 78.6 percent female participants with an average age of 52.7 years, daily step counts declined from an average of 5,047 to 4,487 steps, while moderate-to-vigorous physical activity duration fell from 28 minutes to 22 minutes daily following medication initiation. This represents one of the first objective, large-scale assessments of how GLP-1 adoption correlates with actual behavioral changes in exercise patterns.
The clinical significance of this finding becomes apparent when contextualizing the explosive adoption of GLP-1 medications within contemporary healthcare. Since their initial development for diabetes management, these medications have rapidly transitioned into mainstream weight loss interventions, driven partly by celebrity endorsement and growing evidence of cardiovascular benefits. However, this widespread enthusiasm has perhaps obscured important questions about how these pharmacological interventions influence overall lifestyle patterns and patient behavior. The underlying biology matters considerably: GLP-1 medications work through multiple mechanisms including appetite suppression, delayed gastric emptying, and effects on satiety signaling in the brain. This biological action successfully promotes weight loss without requiring exercise, fundamentally altering the traditional paradigm wherein weight management has long demanded behavioral modifications alongside dietary restriction. The current moment represents a critical juncture in obesity medicine, where practitioners must confront whether pharmaceutical solutions inadvertently undermine the behavioral changes necessary for sustained health outcomes beyond simple weight reduction.
The research methodology provided robust evidence of this phenomenon through objective measurement rather than reliance on self-reported activity levels. Participants in the All of Us Research Program with pre- and post-treatment Fitbit data demonstrated measurable reductions across multiple activity metrics, with the analysis controlling for numerous potential confounding variables. Particularly notable findings emerged regarding differential impacts across demographic groups: males experienced the greatest absolute decline in activity levels, while individuals reporting musculoskeletal pain—itself often correlated with obesity—demonstrated the steepest drops in both step counts and vigorous activity duration. These variations suggest that the reduction in exercise cannot be attributed to a single mechanism but rather reflects complex interactions between pharmacological effects, pain physiology, and gender-specific responses to weight loss. Significantly, the study found no evidence that weight loss itself catalyzed increased physical activity, contradicting the intuitive assumption that lighter body weight would naturally prompt greater movement and exercise engagement.
For healthcare providers managing patients on GLP-1 medications, these findings carry immediate practical implications that extend beyond abstract epidemiological concern. The reduction from 28 to 22 daily minutes of moderate-to-vigorous activity represents a meaningful decline in the cardiovascular and metabolic stimulus necessary for optimal health outcomes. Dr. Mir Ali, medical director of MemorialCare's surgical weight loss center, emphasizes that diminished exercise capacity creates specific physiological risks: reduced muscle preservation during weight loss, increased fatigue symptoms, and suboptimal metabolic adaptation despite pharmaceutical intervention. These consequences prove particularly consequential because resistance training and aerobic exercise provide benefits that pharmacotherapy cannot replicate, including preservation of lean muscle mass, maintenance of bone density, and sustainable long-term weight management. The practical challenge for clinicians involves recognizing that GLP-1 medications may actually increase the resistance patients experience toward physical activity, potentially through medication-related fatigue or the reduced internal motivation that accompanies pharmacologically-induced satiety. This necessitates deliberate clinical strategies, including explicit exercise counseling, structured activity prescriptions, and consideration of resistance training protocols designed for patients experiencing medication-related fatigue.
These findings illuminate a broader tension within contemporary medicine between symptomatic pharmacological intervention and holistic behavioral change. The success of GLP-1 medications in achieving weight loss has inadvertently created conditions wherein both patients and providers may deprioritize exercise as seemingly unnecessary given the medication's efficacy. Yet the evidence base consistently demonstrates that sustained weight management and metabolic health require multi-modal approaches combining dietary modification, regular physical activity, and psychological adaptation. The study's conclusion—that exercise cannot remain optional for GLP-1 users—reflects recognition that pharmaceutical solutions often create new management challenges requiring proactive clinical intervention. This pattern recurs throughout modern medicine: effective pharmacotherapy frequently removes the necessity for behavioral change but simultaneously removes the motivation for such change, potentially leaving patients in worse long-term health positions despite short-term metric improvements. The specific vulnerability of GLP-1 therapy to this dynamic reflects its mechanism of action, which directly addresses appetite and satiety without requiring patient behavioral engagement, thereby eliminating both the challenge and benefit of willful dietary restraint.
Clinicians and health systems must now monitor several specific developments to understand the long-term implications of GLP-1 adoption on population health. First, attention should focus on whether the Endocrine Society, which presented this research at its 2026 annual meeting, incorporates activity recommendations into updated treatment guidelines for GLP-1 therapy. Second, researchers should track longitudinal outcomes for GLP-1 users followed over multiple years, specifically examining whether reduced exercise patterns correlate with accelerated weight regain after medication discontinuation or development of metabolic complications despite weight loss. Third, healthcare organizations should document whether intentional exercise interventions—such as supervised resistance training or structured activity programs integrated with GLP-1 prescription—can reverse the observed decline in physical activity. The research community must also investigate whether the observed fatigue effects respond to dose adjustment, timing modifications, or pharmaceutical interventions that might preserve medication benefits while restoring exercise capacity. Until such evidence emerges, clinicians prescribing GLP-1 medications must explicitly address physical activity as a non-negotiable component of treatment rather than an optional adjunct, recognizing that pharmaceutical weight loss success paradoxically creates greater clinical responsibility for ensuring behavioral health outcomes.
